Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL

Clinical Infectious Diseases

Volumn 55, Issue 12, 2012, Pages 1742-1744

  Rajasingham, Radha ^a,b   Boulware, David R ^c  

^a MAKERERE UNIVERSITY   (Uganda)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ANTIRETROVIRUS AGENT; CRYPTOCOCCAL ANTIGEN; FLUCONAZOLE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LENGTH OF STAY; LETTER; MORTALITY; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

ANTIGENS, FUNGAL; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; MENINGITIS, CRYPTOCOCCAL; SEROLOGIC TESTS;

EID: 84870223798     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis725     Document Type: Letter

References (8)

1. Park BJ, Wannwmuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-30.
2. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007; 12:929-35. (Pubitemid 47245826)
3. Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 2010; 51:448-55.
4. Castelnuovo B, Manabe YC, Kiragga A, Kamya M, Easterbrook P, Kambugu A. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 2009; 49:965-72.
5. Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 2012; 59: E85-91.
6. Centers for Disease Control and Prevention. Late HIV testing-34 states, 1996-2005. MMWR Morb MortalWkly Rep 2009; 58:661-5.
7. WHO. Rapid advice: Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. Geneva: World Health Organization, 2011.
8. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from CDC, the national institutes of health, and the HIV medicine association of the infectious diseases society of America. MMWR Recomm Rep 2009; 58:1-207.